Aug. 1, 2013
/PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release second quarter fiscal year 2013 financial results after the market closes on Wednesday, August 7, 2013. The Company will host a conference call beginning at
5:00 pm Eastern time
, 2:00 pm Pacific time to discuss its results.
Participants can access the call by dialing 877-317-6789 (
) or 412-317-6789 (international). The conference call will also be available via a live webcast on the investor relations section of Depomed's website at
. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
Depomed, Inc. is a specialty pharmaceutical company with four approved and marketed products. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Zipsor ® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug for the management of breakthrough pain in cancer patients
18 years of age and older
who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in
the United States
. Gralise, Glumetza and other product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website,
August J. Moretti Depomed, Inc. 650-462-5900
SOURCE Depomed, Inc.